IN2012DN03361A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03361A
IN2012DN03361A IN3361DEN2012A IN2012DN03361A IN 2012DN03361 A IN2012DN03361 A IN 2012DN03361A IN 3361DEN2012 A IN3361DEN2012 A IN 3361DEN2012A IN 2012DN03361 A IN2012DN03361 A IN 2012DN03361A
Authority
IN
India
Prior art keywords
microparticles
disclosed
treating
macular
methods
Prior art date
Application number
Inventor
Heather Nettles
Angela Stella
Original Assignee
Evonik Degussa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Degussa Corp filed Critical Evonik Degussa Corp
Publication of IN2012DN03361A publication Critical patent/IN2012DN03361A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

Disclosed herein are pharmaceutical compositions comprising microparticles of ranibizumab that are useful for treating or preventing age-related macular degeneration. Also disclosed herein are microparticles that can be used to treat or prevent macular angiogenesis. Further disclosed are methods of making the microparticles and compositions and methods for treating or preventing macular degeneration and diseases, illnesses, or conditions relating to increased or abnormal macular angiogenesis.
IN3361DEN2012 2009-10-01 2010-10-01 IN2012DN03361A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24784809P 2009-10-01 2009-10-01
US24784909P 2009-10-01 2009-10-01
PCT/US2010/051068 WO2011041642A1 (en) 2009-10-01 2010-10-01 Microparticle compositions and methods for treating age-related macular degeneration

Publications (1)

Publication Number Publication Date
IN2012DN03361A true IN2012DN03361A (en) 2015-10-23

Family

ID=43085447

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3361DEN2012 IN2012DN03361A (en) 2009-10-01 2010-10-01

Country Status (7)

Country Link
US (1) US20110104151A1 (en)
EP (1) EP2482804A1 (en)
JP (1) JP2013506693A (en)
KR (1) KR20120095371A (en)
CA (1) CA2776472A1 (en)
IN (1) IN2012DN03361A (en)
WO (1) WO2011041642A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140114208A1 (en) * 2011-05-27 2014-04-24 Novartis Ag Method of treating vision disorders
RU2768492C2 (en) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Polymer protein microparticles
JP6282231B2 (en) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Sustained release biodegradable or bioerodible microspheres or microparticles suspended in a solid depot-forming injectable drug formulation
ES2709351T3 (en) * 2012-09-27 2019-04-16 Allergan Inc Biodegradable drug delivery systems for the sustained release of proteins
BR112015021000A2 (en) 2013-03-14 2017-07-18 Allergan Inc composition of a prolonged release distribution and method of stabilizing proteins during the manufacturing process
KR102016421B1 (en) 2016-10-28 2019-08-30 부산대학교 산학협력단 Composition for preventing or treating macular degeneration comprising surface-modified gold nanoparticles by extract of Gardenia jasminoides
US20220054586A1 (en) * 2018-09-10 2022-02-24 Samsung Bioepis Co., Ltd. Liquid composition comprising protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
AU5741590A (en) 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
EP1802334B1 (en) * 2004-10-21 2012-08-29 Genentech, Inc. Method for treating intraocular neovascular diseases
US20060246146A1 (en) * 2005-04-29 2006-11-02 Mcmahon Robert J Method of increasing the salivary sialic acid content in a mammal
US7918814B2 (en) * 2006-05-02 2011-04-05 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
EP2037977A2 (en) * 2006-06-28 2009-03-25 SurModics, Inc. Active agent eluting matrices with particulates
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
JP2012515790A (en) * 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ， インコーポレイテッド Continuous double emulsion process for fine particle production

Also Published As

Publication number Publication date
US20110104151A1 (en) 2011-05-05
CA2776472A1 (en) 2011-04-07
EP2482804A1 (en) 2012-08-08
JP2013506693A (en) 2013-02-28
WO2011041642A1 (en) 2011-04-07
KR20120095371A (en) 2012-08-28

Similar Documents

Publication Publication Date Title
PH12020550450A1 (en) Certain chemical entities, compositions and methods
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
PH12016500862A1 (en) Autotaxin inhibitor compounds
IN2012DN02469A (en)
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
GB201118656D0 (en) New compounds
IN2012DN03361A (en)
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
SG10201903119QA (en) Polypeptide vaccine
MX2015012435A (en) Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders.
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
MX2015007916A (en) Peri-carbinols.
MX336711B (en) Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders.
MX2012001134A (en) Compositions and methods for inhibition of the jak pathway.
TN2014000131A1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
MX2012006430A (en) Combination preparations comprising a cytokine antagonist and corticosteroid.
IN2015KN00492A (en)
WO2011127048A3 (en) NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX340536B (en) Egfr targeted therapy.
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity